Vantage Consulting Group’s ResMed RMD Stock Holding History

Vantage Consulting Group’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-292	Closed	-$62K	–	1250
2020 Q4	$62K	Buy	+292	New	+$58.2K	0.01%	366

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vantage Consulting Group's RMD Position: Q1 2021 in Review

Vantage Consulting Group sold out of ResMed (RMD) in Q1 2021, closing a stake of 292 shares — an estimated $62K sold.

Vantage Consulting Group first reported a position in RMD in Q4 2020 and held it in 1 quarter. The position peaked at $62K in Q4 2020. 662 funds tracked by Wall St. Rank hold RMD as of Q1 2021.

Vantage Consulting Group reported no remaining ResMed position as of Q1 2021 after selling out during the quarter.
Vantage Consulting Group sold 292 ResMed shares in Q1 2021, an estimated $62K.
Vantage Consulting Group first reported a position in ResMed in Q4 2020 and held it in 1 quarter.
Vantage Consulting Group's ResMed position peaked at $62K in Q4 2020.
662 funds tracked by Wall St. Rank held ResMed as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.